Bristol-Myers Squibb (Belgium)

Recent papers from Bristol-Myers Squibb (Belgium)

1. Bivariate Copula Models With Event‐Free Cure Effect for Survival Extrapolations and Individual‐Level Correlation AnalysisStatistics in Medicine · 2026
2. Multiplexed ChipCytometry for immune cell profiling in colonic tissues of patients with inflammatory bowel diseaseScientific Reports · 2026
3. Mechanistic Insights into Drug Release from PLGA- and PLA-Based ImplantsMolecular Pharmaceutics · 2026
4. Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting SystemMayo Clinic Proceedings Innovations Quality & Outcomes · 2026
5. TRPML1 loss disrupts lysosome–mitochondria homeostasis and sensitizes MDA-MB-231 triple-negative breast cancer cells to chemotherapyJournal of Biological Chemistry · 2026
6. Model‐informed optimal dose selection of golcadomide in combination with R‐CHOP in patients with previously untreated aggressive B‐cell lymphomaBritish Journal of Clinical Pharmacology · 2026
7. Discovery of BMS-986449: A Potent, Selective Degrader of the Transcription Factors IKZF2 (Helios) and IKZF4 (Eos) to Target Regulatory T Cells in Solid TumorsJournal of Medicinal Chemistry · 2026
8. Ion Mobility-Collision Induced Unfolding Detects Stability Shifts within Hidden Protein Conformer FamiliesJournal of the American Society for Mass Spectrometry · 2026
9. Identificationand Studies of Highly Potent and SelectiveHeterobifunctional Galectin-3 DegradersACS Medicinal Chemistry Letters · 2026
10. The Synthetic Roleof PFAS in Drug Substance Manufacturing:An IQ Consortium Working Group Review on the Potential Impact of PFASRestrictions on Patient Access to MedicinesOrganic Process Research & Development · 2026
11. PathMED: An R toolkit for single-sample molecular scoring and machine learning with omics dataBioinformatics · 2026
12. Detection of seizurogenic compounds in human and rat neurons in vitro: A multi-laboratory, multi-model assessmentNeuroToxicology · 2026
13. Interpretable ROI Identification in Brain Image Analysis: Overcoming CNN Black Box Challenges With Kriging‐Enhanced Adaptive SamplingStatistics in Medicine · 2026
14. Shelf-Stable Bis(perfluoroaryl)nickel(II) Complexes for Organometallic Synthesis and CatalysisOrganometallics · 2026
15. Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, plus rituximab (R) versus investigator’s choice (IC) in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) who have received ≥ 1 line of systemic therapy: GOLSEEK-4, a phase (Ph) 3, randomized study.Journal of Clinical Oncology · 2026
16. Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD ± rituximab (R) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Long-term follow-up (f/u) of the phase (Ph) 1/2 CC-99282-NHL-001 study.Journal of Clinical Oncology · 2026
17. TITE-safety: a robust time-to-event safety monitoring approach for clinical trialsBiometrics · 2026
18. Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, + Pola-RCHP in patients (pts) with newly diagnosed aggressive B-cell lymphoma (a-BCL): Safety and 12-month (mo) efficacy results.Journal of Clinical Oncology · 2026
19. From Brewery Waste to Sustainable Aquafeed: Harnessing Nannochloropsis Microalgae for Fishmeal‐Free Gilthead Sea Bream DietsAquaculture Nutrition · 2026
20. Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kineticsMolecular Therapy Advances · 2026